These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
439 related articles for article (PubMed ID: 23933235)
41. Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy. Liu M; Li J; Zhao D; Yan N; Zhang H; Liu M; Tang X; Hu Y; Ding J; Zhang N; Liu X; Deng Y; Song Y; Zhao X Biomaterials; 2022 Apr; 283():121415. PubMed ID: 35217484 [TBL] [Abstract][Full Text] [Related]
42. Particle size-dependent triggering of accelerated blood clearance phenomenon. Koide H; Asai T; Hatanaka K; Urakami T; Ishii T; Kenjo E; Nishihara M; Yokoyama M; Ishida T; Kiwada H; Oku N Int J Pharm; 2008 Oct; 362(1-2):197-200. PubMed ID: 18586076 [TBL] [Abstract][Full Text] [Related]
43. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. Tagami T; Nakamura K; Shimizu T; Yamazaki N; Ishida T; Kiwada H J Control Release; 2010 Mar; 142(2):160-6. PubMed ID: 19850094 [TBL] [Abstract][Full Text] [Related]
44. Comprehensive analysis of PEGylated liposome-associated proteins relating to the accelerated blood clearance phenomenon by combination with shotgun analysis and conventional methods. Kawanishi M; Hashimoto Y; Shimizu T; Sagawa I; Ishida T; Kiwada H Biotechnol Appl Biochem; 2015; 62(4):547-55. PubMed ID: 25196743 [TBL] [Abstract][Full Text] [Related]
45. Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery. Ichihara M; Moriyoshi N; Lila AS; Ishida T; Kiwada H Methods Mol Biol; 2013; 948():35-47. PubMed ID: 23070762 [TBL] [Abstract][Full Text] [Related]
46. Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration. Su Y; Liu M; Liang K; Liu X; Song Y; Deng Y AAPS PharmSciTech; 2018 Oct; 19(7):3210-3218. PubMed ID: 30187444 [TBL] [Abstract][Full Text] [Related]
48. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293 [TBL] [Abstract][Full Text] [Related]
49. The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. Kierstead PH; Okochi H; Venditto VJ; Chuong TC; Kivimae S; Fréchet JMJ; Szoka FC J Control Release; 2015 Sep; 213():1-9. PubMed ID: 26093095 [TBL] [Abstract][Full Text] [Related]
50. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. Ishida T; Ichihara M; Wang X; Yamamoto K; Kimura J; Majima E; Kiwada H J Control Release; 2006 May; 112(1):15-25. PubMed ID: 16515818 [TBL] [Abstract][Full Text] [Related]
52. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance. Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541 [TBL] [Abstract][Full Text] [Related]
53. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. Wang XY; Ishida T; Ichihara M; Kiwada H J Control Release; 2005 May; 104(1):91-102. PubMed ID: 15866337 [TBL] [Abstract][Full Text] [Related]
54. A Maleimide-Terminally Modified PEGylated Liposome Induced the Accelerated Blood Clearance Independent of the Production of Anti-PEG IgM Antibodies. Ishima Y; Yamazaki N; Chuang VTG; Shimizu T; Ando H; Ishida T Biol Pharm Bull; 2022; 45(10):1518-1524. PubMed ID: 36184510 [TBL] [Abstract][Full Text] [Related]
55. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Xu H; Wang KQ; Deng YH; Chen DW Biomaterials; 2010 Jun; 31(17):4757-63. PubMed ID: 20303164 [TBL] [Abstract][Full Text] [Related]
56. Repeated Administration of Hyaluronic Acid Coated Liposomes with Improved Pharmacokinetics and Reduced Immune Response. Zhang Q; Deng C; Fu Y; Sun X; Gong T; Zhang Z Mol Pharm; 2016 Jun; 13(6):1800-8. PubMed ID: 27112287 [TBL] [Abstract][Full Text] [Related]
57. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. Ma Y; Yang Q; Wang L; Zhou X; Zhao Y; Deng Y Eur J Pharm Sci; 2012 Apr; 45(5):539-45. PubMed ID: 22155543 [TBL] [Abstract][Full Text] [Related]
58. Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon. Su Y; Liu M; Xiong Y; Ding J; Liu X; Song Y; Deng Y Drug Deliv Transl Res; 2019 Feb; 9(1):66-75. PubMed ID: 30378014 [TBL] [Abstract][Full Text] [Related]
59. The Contribution of PEG Molecular Weights in PEGylated Emulsions to the Various Phases in the Accelerated Blood Clearance (ABC) Phenomenon in Rats. Jiao J; Jiao X; Wang C; Wei L; Wang G; Deng Y; Song Y AAPS PharmSciTech; 2020 Nov; 21(8):300. PubMed ID: 33140142 [TBL] [Abstract][Full Text] [Related]
60. Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions. Liu M; Zhao D; Yan N; Li J; Zhang H; Liu M; Tang X; Liu X; Deng Y; Song Y; Zhao X Int J Pharm; 2022 Jan; 612():121365. PubMed ID: 34896215 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]